Tower Research Capital LLC (Trc) Eagle Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,702 shares of EGRX stock, worth $2,161. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,702

Previous 3,196 15.46%

Holding current value

$2,161

Previous $17,000 41.18%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.71 - $6.07 $1,832 - $2,998	-494 Reduced 15.46%	2,702 $10,000
Q2 2024 Aug 13, 2024	SELL	$3.34 - $5.6 $1,175 - $1,971	-352 Reduced 9.92%	3,196 $17,000
Q1 2024 May 15, 2024	SELL	$4.26 - $6.51 $14,028 - $21,437	-3,293 Reduced 48.14%	3,548 $18,000
Q4 2023 Feb 13, 2024	BUY	$4.63 - $15.21 $27,298 - $89,678	5,896 Added 623.92%	6,841 $35,000
Q3 2023 Nov 14, 2023	SELL	$15.21 - $22.88 $3,224 - $4,850	-212 Reduced 18.32%	945 $14,000
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $14,050 - $25,241	792 Added 216.99%	1,157 $22,000
Q1 2023 May 09, 2023	BUY	$25.06 - $34.09 $200 - $272	8 Added 2.24%	365 $10,000
Q4 2022 Feb 10, 2023	SELL	$24.98 - $39.77 $189,848 - $302,252	-7,600 Reduced 95.51%	357 $10,000
Q3 2022 Nov 10, 2022	BUY	$26.42 - $47.12 $179,233 - $319,662	6,784 Added 578.35%	7,957 $211,000
Q2 2022 Aug 15, 2022	SELL	$41.26 - $51.35 $59,579 - $74,149	-1,444 Reduced 55.18%	1,173 $52,000
Q1 2022 May 12, 2022	SELL	$44.58 - $52.6 $52,961 - $62,488	-1,188 Reduced 31.22%	2,617 $129,000
Q4 2021 Feb 14, 2022	BUY	$45.82 - $56.9 $121,606 - $151,012	2,654 Added 230.58%	3,805 $194,000
Q3 2021 Nov 15, 2021	BUY	$43.79 - $55.78 $16,859 - $21,475	385 Added 50.26%	1,151 $64,000
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $9,251 - $11,169	-251 Reduced 24.68%	766 $33,000
Q1 2021 May 17, 2021	BUY	$40.32 - $50.97 $33,425 - $42,254	829 Added 440.96%	1,017 $42,000
Q4 2020 Feb 16, 2021	SELL	$41.72 - $51.34 $24,072 - $29,623	-577 Reduced 75.42%	188 $9,000
Q3 2020 Nov 16, 2020	SELL	$37.02 - $51.28 $48,163 - $66,715	-1,301 Reduced 62.97%	765 $32,000
Q2 2020 Aug 13, 2020	BUY	$43.24 - $55.02 $89,333 - $113,671	2,066 New	2,066 $99,000
Q1 2019 May 14, 2019	SELL	$38.66 - $51.82 $4,020 - $5,389	-104 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$36.72 - $67.73 $3,818 - $7,043	104 New	104 $4,000
Q3 2018 Nov 13, 2018	SELL	$66.65 - $83.86 $24,127 - $30,357	-362 Closed	0 $0
Q2 2018 Aug 15, 2018	SELL	$51.25 - $76.62 $81,795 - $122,285	-1,596 Reduced 81.51%	362 $27,000
Q1 2018 May 15, 2018	BUY	$52.16 - $66.86 $89,297 - $114,464	1,712 Added 695.93%	1,958 $103,000
Q4 2017 Feb 09, 2018	BUY	$49.6 - $60.87 $12,201 - $14,974	246	246 $13,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.35M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $10.4M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Eagle Pharmaceuticals, Inc. Transaction History